Moderna is focusing on advancing its mRNA vaccine pipeline for other viruses following a decline in COVID-19 product sales.
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life ...
Moderna shares rose Wednesday after it said that it had received up to $750 million from Blackstone Life Sciences to advance its flu program.
Moderna announced that it had signed a $750 million financing agreement with Blackstone Life Sciences to develop an mRNA flu ...
An arm of the private equity firm pledged up to $750 million in funding for Moderna’s flu shot development, in exchange for milestones and royalties.
Moderna MRNA announced positive results from the pivotal phase III NextCOVE study evaluating mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older ...